Performance of Fully-Automated High-Throughput Plasma Biomarker Assays for Alzheimer’s Disease in Amnestic Mild Cognitive Impairment Subjects

IF 4.3 Q2 BUSINESS

The Journal of Prevention of Alzheimer's Disease Pub Date : 2024-03-19 DOI:10.14283/jpad.2024.58

{"title":"Performance of Fully-Automated High-Throughput Plasma Biomarker Assays for Alzheimer’s Disease in Amnestic Mild Cognitive Impairment Subjects","authors":"","doi":"10.14283/jpad.2024.58","DOIUrl":null,"url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Introduction</h3> <p>Novel plasma biomarkers are promising for identifying Alzheimer’s disease (AD) pathological processes in vivo, but most currently employed assays have limitations precluding widespread use.</p> </span> <span> <h3>Methods</h3> <p>CSF and plasma samples were collected from seventy amnestic mild cognitive impairment (aMCI) subjects, stratified as A+ and A−. CSF Aβ40, Aβ42, p-tau181 and t-tau and plasma Aβ40, Aβ42 and p-tau181 quantification were conducted using the Lumipulse G assays (Fujirebio), to evaluate the diagnostic performance of plasma biomarkers and assess their associations with CSF biomarkers.</p> </span> <span> <h3>Results</h3> <p>All plasma biomarkers except Aβ40 showed a very good accuracy in distinguishing A+ aMCI from A− aMCI, Aβ42/p-tau181 ratio being the most accurate (AUC 0.895, sensitivity 95.1%, specificity 82.8%). Plasma biomarkers levels were significantly associated with CSF biomarkers concentration.</p> </span> <span> <h3>Discussion</h3> <p>High-throughput and fully-automated plasma assays could be helpful in discriminating with high accuracy between aMCI in the AD continuum and aMCI unlikely due to AD in clinical settings.</p> </span>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Prevention of Alzheimer's Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14283/jpad.2024.58","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BUSINESS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Novel plasma biomarkers are promising for identifying Alzheimer’s disease (AD) pathological processes in vivo, but most currently employed assays have limitations precluding widespread use.

Methods

CSF and plasma samples were collected from seventy amnestic mild cognitive impairment (aMCI) subjects, stratified as A+ and A−. CSF Aβ40, Aβ42, p-tau181 and t-tau and plasma Aβ40, Aβ42 and p-tau181 quantification were conducted using the Lumipulse G assays (Fujirebio), to evaluate the diagnostic performance of plasma biomarkers and assess their associations with CSF biomarkers.

Results

All plasma biomarkers except Aβ40 showed a very good accuracy in distinguishing A+ aMCI from A− aMCI, Aβ42/p-tau181 ratio being the most accurate (AUC 0.895, sensitivity 95.1%, specificity 82.8%). Plasma biomarkers levels were significantly associated with CSF biomarkers concentration.

Discussion

High-throughput and fully-automated plasma assays could be helpful in discriminating with high accuracy between aMCI in the AD continuum and aMCI unlikely due to AD in clinical settings.

查看原文本刊更多论文

全自动高通量血浆生物标志物测定在失忆性轻度认知障碍受试者中的应用效果

摘要引言新型血浆生物标记物有望确定阿尔茨海默病（AD）的体内病理过程，但目前使用的大多数检测方法都存在局限性，无法广泛使用。方法收集了 70 名轻度认知障碍（aMCI）患者的脑脊液和血浆样本，将其分为 A+ 和 A-。使用Lumipulse G测定法（Fujirebio）对脑脊液中的Aβ40、Aβ42、p-tau181和t-tau以及血浆中的Aβ40、Aβ42和p-tau181进行定量分析，以评估血浆生物标志物的诊断性能及其与脑脊液生物标志物的关联。结果除 Aβ40 外，所有血浆生物标志物在区分 A+ aMCI 和 A- aMCI 方面都表现出很高的准确性，其中 Aβ42/p-tau181 比值最为准确（AUC 0.895，灵敏度 95.1%，特异性 82.8%）。血浆生物标志物水平与脑脊液生物标志物浓度明显相关。讨论高通量和全自动血浆检测有助于在临床环境中高精度地区分AD连续性AMCI和不可能由AD引起的AMCI。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of Prevention of Alzheimer's Disease Medicine-Psychiatry and Mental Health

CiteScore

9.20

自引率

0.00%

发文量

期刊介绍： The JPAD Journal of Prevention of Alzheimer’Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including: neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and heath economic outcomes.JPAD will publish also the meeting abstracts from Clinical Trial on Alzheimer Disease (CTAD) and will be distributed both in paper and online version worldwide.We hope that JPAD with your contribution will play a role in the development of Alzheimer prevention.